In recent years, the landscape of oncology treatment has undergone significant transformations, particularly in the management of hepatic tumors such as hepatocellular carcinoma (HCC). In the face of an increasing incidence of HCC and a demand for more effective therapeutic strategies, the congress aims to explore the evolution of interventional and immunological treatments, highlighting how these approaches can transform the therapeutic pathway for patients.

The congress aims to:

Discuss recent advancements in IO (Interventional-Oncology) therapy and HCC management, as well as their clinical impact.

Provide a multidisciplinary forum to share knowledge and experiences among experts in the field, fostering exchanges that can enhance the quality of care provided.

Present live clinical cases and interactive discussions that showcase the practical application of the latest techniques and protocols.

The structure of the congress is designed to provide a broad spectrum of knowledge and practical experience. The sessions will cover:

• IO Treatments and Naïve HCC
  Analysis of new treatment options and surgical/percutaneous therapies in HCC, focusing on naïve cases and new therapeutic success probabilities. This session will delve into innovations while addressing topics such as treatment stage migration and therapeutic hierarchy.

• Imaging and Treatment Optimization
  The imaging session will focus on advanced diagnostic techniques, such as CBCT and robotic navigation systems, which enhance intervention accuracy and treatment, highlighting the importance of pre-treatment planning.

• Recurrent Cases and Ongoing Approaches
  Considerations on IO treatments for recurrent HCC, discussing how genomics and radiomic information can be used as tools for evaluating therapeutic endpoints and optimizing clinical decision-making.

• Beyond HCC: IO and mCRC
  This session will provide updates on the latest research on combined treatments for metastatic colorectal cancer (mCRC), with a special focus on promising practices and ESMO guidelines.

• Final Overview and Interactive Discussion
  Open discussion sessions and expert panels will ensure direct participant engagement, aiming to consolidate and share best practices in interventional oncology.

The congress represents a powerful opportunity to deepen the convergence between interventional therapies and immuno-oncology practices. With the involvement of internationally renowned experts, clinical cases, and group discussions, we will examine current and future best practices, centering on how to expand therapeutic options for patients affected by HCC and other hepatic tumors. We appreciate your participation and commitment to the ongoing quest to improve care for oncology patients.